ZTS - Zoetis Inc.

NYSE - NYSE Delayed Price. Currency in USD
91.47
-0.07 (-0.08%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close91.54
Open91.44
Bid82.11 x 1000
Ask109.96 x 800
Day's Range90.67 - 91.79
52 Week Range60.65 - 93.67
Volume2,712,621
Avg. Volume2,532,180
Market Cap44.072B
Beta0.96
PE Ratio (TTM)40.17
EPS (TTM)2.28
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & Yield0.50 (0.55%)
Ex-Dividend Date2018-07-19
1y Target Est93.29
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of ZTS earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Zoetis Inc Earnings Call

  • Business Wire6 days ago

    Zoetis Announces Pricing of $1.5 Billion of Senior Notes

    Zoetis Inc. (ZTS) today announced that it has agreed to sell $1.5 billion of senior notes, consisting of $300 million aggregate principal amount of floating rate senior notes due 2021, $300 million aggregate principal amount of 3.250% senior notes due 2021, $500 million aggregate principal amount of 3.900% senior notes due 2028 and $400 million aggregate principal amount of 4.450% senior notes due 2048, in an underwritten public offering. Zoetis intends to use the net proceeds to repay $500 million drawn under the 364-day revolving credit facility entered into on July 27, 2018, repay $500 million issued under its commercial paper program, and for general corporate purposes. Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters.

  • Moody's7 days ago

    Zoetis Inc. -- Moody's assigns Baa1 to Zoetis' notes offering

    Moody's Investors Service ("Moody's") assigned a Baa1 rating to the proposed senior unsecured notes offering of Zoetis Inc. ("Zoetis"). There are no changes to Zoetis' existing ratings including the Baa1 senior unsecured rating and the Prime-2 commercial paper rating. Proceeds from the notes offerings will be used to repay short term debt that was used in financing the acquisition of Abaxis, Inc. and for general corporate purposes.

  • Investopedia14 days ago

    Is Money Rotating Into Agribusiness and Chemical Stocks?

    Sector rotation in this market continues, and the agribusiness and chemical industries within the materials sector look to be heating up. While their performance on a relative basis is lackluster, on an absolute basis, there are several setups offering reward/risk scenarios skewed in our favor. First, let's take a structural look at the VanEck Vectors Agribusiness ETF ( MOO), which contains exposure to chemical stocks, as there is no exchange-traded fund (ETF) dedicated to that industry.

  • Merck’s Animal Health Business Witnessed Solid Growth in 1H 2018
    Market Realist14 days ago

    Merck’s Animal Health Business Witnessed Solid Growth in 1H 2018

    In the second quarter of 2018, Merck’s (MRK) Animal Health business generated revenues of $1.1 billion compared to $955.0 million in the second quarter of 2017, reflecting ~14% growth on a year-over-year (or YoY) basis and 2% growth sequentially. In the second quarter of 2018, in the US market and international markets (outside the U.S. markets), Merck’s Animal Health business generated revenues of $311.0 million and $779.0 million, respectively, reflecting ~15% and ~14% YoY growth.

  • Investor's Business Daily14 days ago

    Should You Buy Apple Now? Plus, A Look At 4 Other Bullish Charts

    Apple leads five top stocks to watch that are in or near buy range and showing relative strength. CSX, Ross Stores, Zoetis and PerkinElmer are also triggering a bullish technical signal.

  • TheStreet.com17 days ago

    Zoetis Surges to New Highs: Where to Buy It Now

    Prices had been trading sideways to slightly higher since March but a big rally Thursday pushed share prices to new highs. In this daily bar chart of ZTS, below, we can see Thursday's upside breakout. The daily On-Balance-Volume (OBV) line has been in a neutral or flat trend from late February and shows some softness the past month.

  • Eli Lilly’s Q2 2018 Earnings: Elanco
    Market Realist17 days ago

    Eli Lilly’s Q2 2018 Earnings: Elanco

    Elanco is Eli Lilly & Co.’s (LLY) animal health business. Elanco reported revenues of $792.1 million in the second quarter, representing 1.0% YoY (year-over-year) growth from $784.8 million in the second quarter of 2017. The chart below shows Elanco’s revenues since the first quarter of 2017.

  • TheStreet.com17 days ago

    3 Great Stocks to Buy If You Love Your Pet

    The animal health market continues to be strong, and so is the outlook. Here are several plays on the space and why you should make them.

  • TheStreet.com17 days ago

    Jim Cramer: 4 Pet-Related Stocks That Are Top Dog

    Like Benno Dorer, the CEO of Clorox, Zoetis' CEO Juan Ramón Alaix also comes on Mad Money. What shocked me when I dug down is what stood out as the biggest growers in its panoply of products: new products for companion animals. Now, the humanization of pets has been a continual theme of Mad Money for ages.

  • Investor's Business Daily17 days ago

    Apple, Tesla Are Soaring, But Be Wary: Dow Jones Futures

    Apple surged to a $1 trillion market cap Thursday, but shares are extended. Tesla stock soared, but is well off a buy point. Focus on top stocks in a buy zone or setting up.

  • Investor's Business Daily18 days ago

    Teva Pharma Dives As Another Drugmaker Breaks Out On Earnings

    Teva Pharmaceutical stock plunged on its mixed second quarter results Thursday as full-year guidance came in light and fellow drugmaker Zoetis beat quarterly views.

  • Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View
    Zacks18 days ago

    Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View

    Zoetis second-quarter 2018 results exceed both earnings and sales estimates. The company completes the acquisition of Abaxis, Inc.

  • Zoetis (ZTS) Q2 Earnings and Revenues Beat Estimates
    Zacks18 days ago

    Zoetis (ZTS) Q2 Earnings and Revenues Beat Estimates

    Zoetis (ZTS) delivered earnings and revenue surprises of 8.45% and 2.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press18 days ago

    Zoetis: 2Q Earnings Snapshot

    The Parsippany, New Jersey-based company said it had net income of 79 cents per share. Earnings, adjusted for non-recurring gains, came to 77 cents per share. The results exceeded Wall Street expectations. ...

  • Business Wire18 days ago

    Zoetis Announces Second Quarter 2018 Results

    Zoetis $ZTS reports 2Q18 financial results.

  • Benzinga19 days ago

    Zoetis Q2 Earnings Preview

    On Thursday, Zoetis (NYSE: ZTS ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Zoetis EPS is expected to be ...

  • Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More
    Zacks19 days ago

    Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More

    Let's see how these pharma/biotech stocks are poised ahead of their scheduled results on Aug 2.

  • Investopedia19 days ago

    4 Blue-chip Stocks Offering Ultra-high Returns

    Per Barron's, these four stocks are standouts in this regard: health insurer UnitedHealth Group Inc. ( UNH), animal drug and vaccine producer Zoetis Inc. ( ZTS), semiconductor maker Nvidia Corp. ( NVDA) and payments processor Mastercard Inc. ( MA). Dividend growth rates are the average annual increases recorded over the past 5 years.

  • PR Newswire19 days ago

    Triumph Bancorp Set to Join S&P SmallCap 600

    NEW YORK , July 31, 2018 /PRNewswire/ -- Triumph Bancorp Inc. (NASD: TBK) will replace Abaxis Inc. (NASD: ABAX) in the S&P SmallCap 600 effective prior to the open of trading on Monday, August 6 . S&P ...

  • Business Wire19 days ago

    Zoetis Completes Acquisition of Abaxis, a Leading Global Provider of Veterinary Point-of-Care Diagnostic Instruments

    Zoetis Inc. (ZTS) today announced the completion of the acquisition of Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 billion in aggregate. The acquisition, which was first announced on May 16, follows the satisfaction of all conditions to the closing, including the receipt of the approval of the acquisition by Abaxis shareholders at a shareholder meeting earlier today.

  • Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?
    Zacks20 days ago

    Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?

    We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.

  • Market Exclusive20 days ago

    Market Morning: PCE Inflation, California Burning, Lab Grown Mouse Meat & Apple Earnings

    Futures Steady With Inflation Data on Tap, Fed Decision Tomorrow Stock futures are floating slightly higher this morning as the Personal Consumption Expenditures index data are due at 8:30am Eastern. Market expectations for the Core PCE, excluding food and energy prices, are for a 2% year over year rise. Anything significantly above that and we […] The post Market Morning: PCE Inflation, California Burning, Lab Grown Mouse Meat & Apple Earnings appeared first on Market Exclusive.

  • See what the IHS Markit Score report has to say about Zoetis Inc.
    Markit23 days ago

    See what the IHS Markit Score report has to say about Zoetis Inc.

    Short interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. ETFs that hold ZTS had net inflows of $657 million over the last one-month.